RenovoRx: Balancing Near-Term Sales with a Pivotal Cancer Trial

MOUNTAIN VIEW, CA – July 29, 2026

In the high-stakes world of biotechnology, companies often exist as a binary proposition: either they are burning through cash in pursuit of a clinical breakthrough, or they are a commercial entity focused on sales and marketing. RenovoRx, Inc. (Nasdaq: RNXT) is charting a more complex, and potentially more resilient, path. The company’s recent announcement of its second-quarter 2026 conference call, scheduled for August 12th, puts a spotlight on a dual-pronged strategy that is increasingly rare: generating tangible revenue from an FDA-cleared medical device while simultaneously advancing a potentially transformative therapy through a late-stage clinical trial for one of the world's deadliest cancers.

While the upcoming call is ostensibly a financial report, it serves as a critical progress check on this two-track approach. On one hand, investors will be scrutinizing the sales figures for RenovoCath®, the company's patented drug-delivery catheter. On the other, the medical and patient communities will be listening for updates on the Phase III TIGeR-PaC trial, which is nearing a crucial enrollment milestone and holds significant promise for patients with locally advanced pancreatic cancer. How RenovoRx balances these two priorities—near-term commercial execution and long-term clinical ambition—will define its trajectory and its ultimate impact on both shareholder value and patient lives.

Building a Commercial Foundation

Cutting through the hype of future promises, the most immediate measure of RenovoRx’s progress lies in its commercial performance. The company is actively selling its RenovoCath device as a standalone product, and the numbers indicate a clear and accelerating growth curve. After booking approximately $1.1 million in its first full year of commercialization in 2025, RenovoRx reported a record $563,000 in the first quarter of 2026 alone. This puts the company well on its way to achieving its full-year 2026 revenue guidance of $3 to $4 million.

This isn't just a story of numbers; it's a story of adoption. The device is gaining traction where it matters most: in high-volume, prestigious U.S. cancer centers. The number of active commercial sites using RenovoCath grew from just five at the start of 2025 to sixteen by the end of Q1 2026, with a growing base of repeat orders signaling physician confidence. This strategy of targeting National Cancer Institute-designated centers is a deliberate move to build credibility and establish a strong foothold in the oncology community.

This commercial revenue stream is more than just a line item on a balance sheet. For a clinical-stage company, it is a vital source of non-dilutive funding that helps fuel its extensive research and development pipeline. With an estimated peak annual U.S. market of around $400 million for RenovoCath as a standalone device, this commercial engine provides a strategic buffer, de-risking the company’s reliance on the binary outcomes of clinical trials and providing a solid foundation for future growth.

A Critical Juncture for Pancreatic Cancer

While RenovoCath sales provide the financial foundation, the TIGeR-PaC trial represents the company's moonshot. The study is evaluating a drug-device combination that uses the RenovoCath to deliver the chemotherapy drug gemcitabine directly into the arteries feeding a pancreatic tumor. This is a direct challenge to the current standard of care for locally advanced pancreatic cancer (LAPC), a devastating disease with a five-year survival rate of just 13%.

Patients with LAPC are typically not candidates for surgery, and while systemic intravenous (IV) chemotherapy can offer some benefit, it comes at the cost of debilitating side effects as the toxic drugs circulate throughout the body. RenovoRx's approach aims to fundamentally change this risk-reward calculus. The upcoming earnings call is expected to confirm that the TIGeR-PaC trial is on the cusp of full enrollment, a major operational and clinical milestone. With final data anticipated in mid-to-late 2027, the trial is entering its final and most critical phase.

Early interim data from a related study has already provided a beacon of hope, indicating that this targeted intra-arterial approach led to improved overall and progression-free survival compared to systemic therapy, all while significantly reducing severe adverse events. For patients and their families, this is where the tangible impact of innovation is felt—the potential for a more effective treatment with a more tolerable side effect profile.

The Science of Precision Delivery

The technology underpinning both RenovoRx's commercial device and its clinical pipeline is the Trans-Arterial Micro-Perfusion (TAMP™) therapy platform. The concept is elegantly simple: instead of flooding the entire body with chemotherapy, use the RenovoCath device to navigate the body's arterial pathways directly to the tumor. Once in position, the device's unique dual-balloon design temporarily isolates a section of the artery, allowing the chemotherapy to be infused at high pressure, bathing the tumor in a concentrated dose while minimizing escape into the systemic bloodstream.

Recent pharmacokinetic data presented at the 2026 ASCO Annual Meeting provided scientific validation for this approach, showing that TAMP delivery of gemcitabine could increase local drug potency while reducing systemic exposure. This is precision medicine in action, moving beyond genetic markers to a new dimension of anatomical targeting.

This platform strategy also provides significant optionality. The company is not tied to a single drug. It has already secured FDA Orphan Drug Designation not only for its gemcitabine combination but also for using its platform to deliver oxaliplatin, another key chemotherapy agent for pancreatic cancer. This strategic use of the regulatory pathway provides powerful incentives, including seven years of market exclusivity upon approval and significant reductions in development costs. By building a pipeline around a versatile delivery platform rather than a single compound, RenovoRx is creating a durable and expandable oncology franchise. The upcoming call will offer the latest evidence of whether this carefully constructed strategy is unfolding as planned.